Mmbg Investment Advisors CO. Has $7.54 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mmbg Investment Advisors CO. raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,501 shares of the medical research company’s stock after buying an additional 185 shares during the period. Thermo Fisher Scientific accounts for 0.8% of Mmbg Investment Advisors CO.’s holdings, making the stock its 26th largest holding. Mmbg Investment Advisors CO.’s holdings in Thermo Fisher Scientific were worth $7,544,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also bought and sold shares of the stock. Cypress Advisory Group LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $253,000. S.E.E.D. Planning Group LLC grew its position in shares of Thermo Fisher Scientific by 6.2% in the 4th quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company’s stock worth $5,528,000 after buying an additional 618 shares during the last quarter. Czech National Bank raised its position in Thermo Fisher Scientific by 6.6% during the 4th quarter. Czech National Bank now owns 82,934 shares of the medical research company’s stock worth $43,145,000 after buying an additional 5,118 shares during the last quarter. Granite Bay Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $4,758,000. Finally, Courier Capital LLC grew its holdings in Thermo Fisher Scientific by 148.8% in the 4th quarter. Courier Capital LLC now owns 20,914 shares of the medical research company’s stock valued at $10,880,000 after buying an additional 12,509 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Raymond James restated an “outperform” rating and set a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Morgan Stanley raised their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Citigroup cut their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, StockNews.com cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Friday, April 25th. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $607.43.

Thermo Fisher Scientific Stock Down 1.9%

Shares of Thermo Fisher Scientific stock opened at $402.93 on Monday. The company has a market cap of $152.10 billion, a P/E ratio of 24.38, a PEG ratio of 2.99 and a beta of 0.82. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12-month low of $401.75 and a 12-month high of $627.88. The company’s fifty day simple moving average is $464.67 and its two-hundred day simple moving average is $514.56.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the company posted $5.11 earnings per share. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.09%.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. This trade represents a 25.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.